The Advanced liver cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Advanced liver cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced liver cancer Market.

Some of the key takeaways from the Advanced liver cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Advanced liver cancer treatment therapies with a considerable amount of success over the years. 
• Advanced liver cancer companies working in the treatment market are Takeda, Arbele, Eureka Therapeutics, ImmVira Pharma Co. Ltd, Surface Oncology, Vaxcell Bio, SOTIO Biotech, Can-Fite BioPharma, Polaris Pharmaceuticals, and others, are developing therapies for the Advanced liver cancer treatment 

• Emerging Advanced liver cancer therapies such as – TAK-500, ARB202, ET140203, T3011, SRF388, Vax-NK/HCC, SOT101, Namodenoson, ADI-PEG20, and others are expected to have a significant impact on the Advanced liver cancer market in the coming years.   
• In March 2023, In order to determine the effectiveness and safety of Namodenoson in the treatment of advanced hepatocellular carcinoma in patients with ChildPugh class B7 cirrhosis, Can-Fite BioPharma started a Phase III, randomised, double-blind, placebo-controlled trial
• In June 2022, Teclison announced that a study demonstrating the safety, tolerability, and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer, had been published in a peer-reviewed journal.In early- and intermediate-stage liver cancer patients, including those who experienced progression or recurrence following standard therapy, tirapazamine (TPZ) with conventional trans-arterial chemoembolization showed promising effectiveness signs and a good safety profile
• In May 2022, Three confirmed partial responses in three different solid tumour forms—NSCLC, RCC, and HCC—showed therapeutic activity for SRF388 in these solid tumour types. Two patients who received SRF388 monotherapy treatment for clear cell renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) both experienced confirmed partial responses (PR). Additionally, a PR was seen in a patient who received SRF388 and pembrolizumab together for the treatment of hepatocellular carcinoma (HCC)

Advanced liver cancer Overview

The most frequent primary liver cancer is hepatocellular carcinoma (HCC), which is also the main cause of cancer-related death globally. HCC often manifests at an advanced stage in those with cirrhosis brought on by chronic hepatitis (B or C) or alcohol usage.

Get a Free Sample PDF Report to know more about Advanced liver cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight

Emerging Advanced liver cancer Drugs Under Different Phases of Clinical Development Include:

• TAK-500: Takeda
• ARB202: Arbele
• ET140203: Eureka Therapeutics
• T3011: ImmVira Pharma Co. Ltd
• SRF388: Surface Oncology
• Vax-NK/HCC: Vaxcell Bio
• SOT101: SOTIO Biotech
• Namodenoson: Can-Fite BioPharma
• ADI-PEG20: Polaris Pharmaceuticals

Advanced liver cancer Pipeline Therapeutics Assessment

• Advanced liver cancer Assessment by Product Type
• Advanced liver cancer By Stage and Product Type
• Advanced liver cancer Assessment by Route of Administration
• Advanced liver cancer By Stage and Route of Administration
• Advanced liver cancer Assessment by Molecule Type
• Advanced liver cancer by Stage and Molecule Type

DelveInsight’s Advanced liver cancer Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Advanced liver cancer product details are provided in the report. Download the Advanced liver cancer pipeline report to learn more about the emerging Advanced liver cancer therapies

Some of the key companies in the Advanced liver cancer Therapeutics Market include:

Key companies developing therapies for Advanced liver cancer are –  Genentech, Virogin Biotech,  Beijing Immunochina Medical Science & Technology Co., Ltd., Mina Alpha Limited, Amgen, Jiangsu HengRui Medicine Co., Ltd., Abbisko Therapeutics Co, Ltd,  Medivir, Glaxo SmithKline, Teclison, Genoscience Pharma, Eureka Therapeutics Inc., Qurient Co., Ltd., Bristol-Myers Squibb, Lion TCR Pte. Ltd., Leap Therapeutics, TriSalus Life Sciences, Inc., Highlight Therapeutics, Hoffmann-La Roche, Provectus Biopharmaceuticals, Inc., Pfizer, Eisai Inc., GenVivo, Inc., Tvardi Therapeutics, Shanghai Miracogen Inc., Takeda, Bavarian Nordic, Intensity Therapeutics, Arbele Pty Ltd, Quadriga Biosciences, Inc., Klus Pharma, and others.

Advanced liver cancer Pipeline Analysis:

The Advanced liver cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced liver cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced liver cancer Treatment.
• Advanced liver cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced liver cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced liver cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced liver cancer drugs and therapies

Advanced liver cancer Pipeline Market Drivers

• Increasing Prevalence in Advanced liver cancer, increasing research and development investments for the development of novel therapies are some of the important factors that are fueling the Advanced liver cancer Market.

Advanced liver cancer Pipeline Market Barriers

• However, side-effects associated with the treatment of Advanced liver cancer, cost associated with the treatment and other factors are creating obstacles in the Advanced liver cancer Market growth.

Scope of Advanced liver cancer Pipeline Drug Insight    

• Coverage: Global
• Key Advanced liver cancer Companies: Takeda, Arbele, Eureka Therapeutics, ImmVira Pharma Co. Ltd, Surface Oncology, Vaxcell Bio, SOTIO Biotech, Can-Fite BioPharma, Polaris Pharmaceuticals, and others
• Key Advanced liver cancer Therapies: TAK-500, ARB202, ET140203, T3011, SRF388, Vax-NK/HCC, SOT101, Namodenoson, ADI-PEG20, and others
• Advanced liver cancer Therapeutic Assessment: Advanced liver cancer current marketed and Advanced liver cancer emerging therapies
• Advanced liver cancer Market Dynamics: Advanced liver cancer market drivers and Advanced liver cancer market barriers 

Request for Sample PDF Report for Advanced liver cancer Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services